A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
Conditions
Gastric Cancer Adenocarcinoma Metastatic · Gastroesophageal Adenocarcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
AUS Site 2, Darlinghurst, New South Wales, Australia
AUS Site 5, Westmead, New South Wales, Australia
AUS Site 1, Birtinya, Queensland, Australia
AUS Site 4, Clayton, Victoria, Australia
AUS Site 3, Heidelberg, Victoria, Australia
SK Site 2003, Seongnam-si, South Korea
SK Site 2001, Seoul, South Korea
SK Site 2002, Seoul, South Korea
SK Site 2004, Seoul, South Korea
SK Site 2005, Seoul, South Korea
TWN Site 9004, Kaohsiung City, Taiwan
TWN Site 9005, Kaohsiung City, Taiwan
TWN Site 9001, Taichung, Taiwan
TWN Site 9003, Taipei, Taiwan
TWN Site 9006, Taipei, Taiwan
TWN Site 9002, Taoyuan, Taiwan
Study leads
Bolt Clinical Development
Study Director
Bolt Biotherapeutics